Team VPE

  1. Home
  2. Research Teams
  3. Artificial Intelligence
  4. Team VPE

Artificial Intelligence

Team VPE

Next Generation Virtual Patient Engine for Clinical Translation of Drug Candidates

The goal of team VPE is to develop a versatile computational platform that can predict the efficacy of first- or best-in-class drug candidates in virtual patient populations at an unprecedented accuracy, thereby addressing one of the most critical bottlenecks of the pharmaceutical industry today: a 90% failure rate of new drug candidates during clinical development. In partnership with Sanofi, the VPE team will develop innovative artificial intelligence methods to build the virtual patient platform. As a proof-of-concept, the initial platform will focus on chronic immune-mediated diseases such as atopic dermatitis (AD) and inflammatory bowel disease (IBD), where new medication that can address patient heterogeneity is needed.

 Mentors
  • Dr. Thomas Klabunde (Industry Mentor)
    Global Head of Translational Disease Modeling in Data & Data Sciences, Sanofi
  • Dr. Jan Korbel (Academic Mentor)
    Head of Data Science, European Molecular Biology Laboratory

You can also find us on GitHub

Team Location BioMed X Institute Heidelberg

The research of this team is kindly supported by Sanofi.

Our Team Members

Dr. Douglas McCloskey

Group Leader

 Short Bio
  • 2021 – 2022: Chief Scientist, co-founder of AliveX Biotech, Shanghai, China
    • Leading the development of an advanced immune systems biology platform for the identification of biomarkers and drug targets in cancer, autoimmunity, and neurology
  • 2018 – 2021: Group leader, Center for Biosustainability, Technical University of Denmark, Kongens Lyngby, Denmark
    • Leading a group of researchers, including analytical chemists and automation & software engineers, to develop big–omics data generation workflows along with advanced machine learning and biochemical modeling algorithms to learn from this type of data
  • 2017: Postdoc at the Center for Biosustainability, Technical University of Denmark, Kongens Lyngby, Denmark
  • 2010 – 2016: PhD in Bioengineering, University of California, San Diego, USA
 Contact

Dr. Gurdeep Singh

Bioinformatician

 Short Bio
  • 2021 – 2023: PostDoc, Russell lab, Heidelberg University, Germany
  • 2017 – 2021: PhD, Russell lab, Heidelberg University, Germany
  • 2015 – 2017: Research Assistant, Heidelberg University, Germany
  • 2014 – 2015: Bachelor’s thesis at Vrije Universiteit Brussel, Belgium &Heidelberg University, Germany
  • 2010 – 2015: Bachelor of Engineering (Electrical and Electronics), BITS Pilani, India
 Contact

Dr. Lilija Wehling

Computational Biologist

 Short Bio
  • 2021 – 2022: Postdoctoral researcher at the Molecular Hepatopathology Laboratory, Heidelberg University Hospital
  • 2017 – 2021: PhD Student in Systems Biology at BioQuant (Heidelberg University) and the Pathology Institute of the Heidelberg University Hospital
  • 2013 – 2016: Master of Science in Systems Biology, Heidelberg University
 Contact

Dr. Ahmad Wisnu Mulyadi

Algorithm Researcher

 Short Bio
  • 2018 – 2024: PhD in the Dept. of Brain & Cognitive Engineering, Korea University, South Korea
  • 2015 – 2016: Master of Engineering in the Dept. of Interdisciplinary Program of Information Systems, Pukyong National University, South Korea
  • 2013 – 2016: Master of Science in the Dept. of Electrical Engineering, Institut Teknologi Bandung, Indonesia
 Contact

Sanjana Balaji Kuttae

Computational Biologist, Research Assistant

 Short Bio
  • 2018 – 2023: Master of Science in Bioinformatics, Universität des Saarlandes, Saarbrücken, Germany
  • 2011 – 2015: Bachelor of Technology in Bioinformatics, SRM University, Chennai, India
 Contact

Learn more about BioMed X

Team BDB

Team BDB

The objective of the research group is to develop an in vivo continuous monitoring biosensor for direct detection of small molecule biomarkers in brain tissue of rodent models for elucidating pharmacodynamic (PD) effect and pharmacokinetic (PK) parameters of drugs against neuropsychiatric diseases.

Read more

Team TMI

Team TMI

The project’s cores are to develop a ligand specific for a target cell and establish quantitative assessment methods to monitor macromolecular drug delivery across the intestinal epithelial barrier.

Read more